[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale reported: ANI Pharmaceuticals director Patrick D. Walsh disposed of 9,000 shares of ANIP common stock on 08/15/2025 at $89.05 per share, according to this Form 4. After the sale he beneficially owned 70,048 shares. The form was signed by an attorney-in-fact on 08/18/2025. No derivative transactions or additional explanations are disclosed.

Insights

Corporate Governance Expert

TL;DR A director reported a routine open-market sale reducing holdings to 70,048 shares; no derivatives or related-party notes were disclosed.

The filing shows a single non-derivative sale of 9,000 shares on 08/15/2025 at $89.05, leaving the director with 70,048 shares. This appears to be a straightforward Section 16 disclosure with no accompanying plan reference or 10b5-1 notation in the text provided. From a governance view, clarity would increase if the filing referenced a trading plan or reason for the sale, but none is shown.

Securities Analyst

TL;DR Insider sold a modest block of shares; transaction size relative to remaining holdings appears limited and non-material on its own.

The sale of 9,000 shares at $89.05 is documented as a direct disposition. The report does not state that the sale was pursuant to a Rule 10b5-1 trading plan. For investors, this is a routine disclosure required under Section 16; the filing contains no additional operational or financial data to alter an investment thesis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Patrick D

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S		9,000	D	$89.05	70,048	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Patrick D. Walsh, by attorney-in-fact Meredith W. Cook	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANIP director Patrick D. Walsh report?

The director reported a sale of 9,000 shares of ANIP common stock on 08/15/2025 at a price of $89.05 per share.

How many ANIP shares does Patrick D. Walsh own after the reported sale?

After the sale the reporting person beneficially owned 70,048 shares.

Was the Form 4 filing signed and when?

Yes; the Form 4 was signed by an attorney-in-fact on behalf of Patrick D. Walsh on 08/18/2025.

Does the filing show any derivative transactions or 10b5-1 plan reference?

No. The filing discloses only a non-derivative sale and does not reference any derivative transactions or a Rule 10b5-1 trading plan in the provided text.

What relationship does the reporting person have to ANI Pharmaceuticals (ANIP)?

The reporting person is identified as a Director of ANI Pharmaceuticals, Inc.